SCHEMBL8437528

SCHEMBL8437528

CC(C)CC(C=O)NC(CCNC(=O)c1ccc(-c2ccccc2)cc1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.63
RAB9A P51151 2/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
DRD2 P14416 2/20 0.47
DRD4 P21917 2/20 0.47
DRD3 P35462 2/20 0.47
CTSB P07858 1/20 0.46
ACE P12821 1/20 0.44
TRPV1 Q8NER1 2/20 0.43
HIF1A Q16665 1/20 0.43
HPGD P15428 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
EPHX2 P34913 1/20 0.42
MMP1 P03956 2/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
MMP14 P50281 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5869095 0.87 NPC1 (0.71) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL5869102 0.87 NPC1 (0.71) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL5869108 0.87 NPC1 (0.71) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL8436817 0.80 MMP9 (0.48) MMP1MMP2MMP9MMP14HDAC1
SCHEMBL8436408 0.79 TACR1 (0.42) NPC1RAB9ASMN1; SMN2
SCHEMBL8429989 0.79 ACE (0.55) RAB9AACEHPGDMMP1MMP2
SCHEMBL1927508 0.79 NPC1 (1.00) NPC1RAB9ASMN1; SMN2DRD2DRD4
SCHEMBL8437542 0.78 POLB (0.55) DRD2DRD4DRD3ACE
SCHEMBL8436260 0.77 ACE (0.73) SMN1; SMN2ACEHPGDMMP1MMP2
SCHEMBL5869828 0.77 NPC1 (0.66) NPC1RAB9ASMN1; SMN2DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof ACE, ACE2, AGTR2 NPC1 2323/4885RAB9A 2897/4885SMN1; SMN2 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.